Daniel Camardo Email Address

Chief Executive Officer and Board Director at Athersys, Inc

This week, Horizon Pharma announced that our Phase 3 STEADFAST trial, which involved evaluating one of our current medicines for the treatment of Frie

Pharmaceutical/Biotech executive experienced in commercial strategy, operations, analytics, market access, general management and building effective teams. Proven track record of transforming single product start-ups into high functioning multi-franchise organizations. Contributed to a successful US commercial entry of Yamanouchi Pharma in 2003 thru a merger with Fujisawa in 2005 to create Astellas Pharma, a global specialty pharmaceutical company with $3.2B in US net sales (FY2014). Joined Horizon Therapeutics in 2015 as a small specialty pharmaceutical company with ~$2B market cap and helped transform the commercial organization to become a leader in rare disease with 11 on market products and a ~$21B market cap (Jan 2022). Successfully launched 11 products (NDA’s and BLA’s) in specialty markets: Oncology, Urology, Immunology, Neurology, Dermatology, CV Imaging, Rheumatology and Orphan/Rare Disease.